The arylamine N-acetyltransferases (NATs) are involved in the metabolism of a variety of different compounds that we are exposed to on a daily basis. Many drugs and chemicals found in the environment, such as those in cigarette smoke, car exhaust fumes and in foodstuffs, can be either detoxified by NATs and eliminated from the body or bioactivated to metabolites that have the potential to cause toxicity and/or cancer. NATs have been implicated in some adverse drug reactions and as risk factors for several different types of cancers. As a result, the levels of NATs in the body have important consequences with regard to an individual's susceptibility to certain druginduced toxicities and cancers. This review focuses on recent advances in the molecular genetics of the human NATs.
Introduction
The arylamine N-acetyltransferases (NATs) are found in nearly all species from bacteria to humans. They catalyse the acetyltransfer from acetylcoenzyme A to an aromatic amine, heterocyclic amine or hydrazine compound. In humans, acetylation is a major route of biotransformation for many arylamine and hydrazine drugs, as well as for a number of known carcinogens present in the diet, cigarette smoke and the environment. [1] [2] [3] [4] The reaction pathway is catalysed by two cytoplasmic acetyltransferases (NAT; EC 2.3.1.5), N-acetyltransferase Type I (NAT1) and N-acetyltransferase Type II (NAT2). The genes encoding both proteins were first isolated in 1989 by Grant et al who showed that each consists of an intronless open reading frame of 870 base pairs. 5 The two genes are 87% homologous and are located at 8p22, [6] [7] [8] a chromosomal region commonly deleted in human cancers. [9] [10] [11] [12] [13] Ohsako and Deguchi isolated the transcript for each gene from a human liver cDNA library in 1990.
14 Sequencing of NAT1 and NAT2 revealed a number of allelic variants that affect activity of both genes in vivo. This work provided a genetic understanding for the long known functional polymorphism in NAT2 activity 15 and, more recently, in NAT1 activity. [16] [17] [18] Genetic variation modulates the acetylator status of individuals and therefore may impact upon their predisposition to toxicity and disease. This review focuses on the genomics of the arylamine N-acetyltransferases and the impact of genetic variation of the enzymes on drug response in humans.
THE ARYLAMINE N-ACETYLTRANSFERASE GENE FAMILY
To date, 22 NAT-like genes have been identified in 14 different prokaryotic and eukaryotic species, although it is likely that additional genes will be discovered as more genomes become sequenced. The genes invariably have an intronless coding sequence that encodes for a protein between 254 and 332 amino acids in length (Figure 1 ). Figure 1 shows a multiple sequence alignment for 22 NAT proteins. The highest conserved regions occur at the amino terminus, whereas the carboxyl terminus shows very little conservation between species. Consistent with the recently published crystal structure for the Salmonella typhimurium NAT, 19 all NATs possess a conserved cysteine, histidine and aspartate that have been implicated to form a catalytic triad. Inhibitor studies 20 and site-directed mutagenesis studies 21 have confirmed that the cysteine (Cys 68 in the human proteins) is crucial for NAT activity.
A phylogenetic tree for the NAT proteins is shown in Figure 2 . It indicates the separate clustering of the prokaryotic and eukaryotic sequences, with the exception of A. mediterranei NAT which is distant from both groups. This enzyme is part of the rifamycin B synthesis pathway and catalyses the final amide bond formation reaction. 22 The NAT1 and NAT2 sequences for rat, mouse and hamster cluster together suggesting that the two proteins are encoded by genes that were present before the divergence of the three rodent species. By contrast, the two human proteins are more closely related to each other, perhaps because the genes duplicated later in evolution. The general relationship of the amino acid sequences is similar to that recently published for a limited number of NAT nucleotide sequences. 23 
STRUCTURAL CHARACTERISTICS OF THE NAT PROTEINS
The first crystal structure of an arylamine N-acetyltransferase was recently published. 19 Although the NAT was of bacterial origin, it revealed a number of surprising features that provided novel structural and functional information about the enzyme. 19 Specifically, a cysteine-histidine-aspartate catalytic triad was identified in the N-terminus of the protein.
Based on structural analysis, the protein has been divided into three domains. The first consists of a helical bundle, located from amino acid 1 to approximately 90 (based on numbering in Figure 1 ), which forms one side of a cleft in which the cysteine involved in acetyl transfer resides. All NATs are highly homologous in this region. The second domain consists of residues from approximately 90 to 210 and is located on the other side of the cleft. It mostly consists of ␤-sheet structures. The last domain at the carboxyl terminus is a combination of ␤-sheets and ␣-helices, and this region shows the greatest diversity between species. The structural features surrounding the triad are similar to the cysteine protease superfamily of proteins which includes the transglutaminases, cathepsins and caspases. While these proteins traditionally catalyse the hydrolysis of amide substrates, the NATs and the transglutaminases catalyse an acyltransfer that results in amide bond formation. This is also the case for the NAT homolog found in A. mediterranei. 22 To date, the crystal structure of the human NATs has not been resolved although the homology with NAT from bacteria suggests similar features will be present.
www.nature.com/tpj N-ACETYLTRANSFERASE NOMENCLATURE The first attempt to devise a consensus nomenclature for the NATs was published in 1995 and included genes from six species and a total of 39 alleles. 15 Since then, many new alleles have been identified and the nomenclature for these was updated in 2000. 24 The Human Gene Nomenclature Committee has agreed that the symbol NAT be assigned to the arylamine N-acetyltransferase genes. Currently, NAT also is used for unrelated genes such as yeast protein N-terminal acetyltransferase, human noradrenalin transporter, eukaryotic translation initiation factor, translation repressor protein and death associated protein 5.
The classification of the eukaryotic genes into NAT1 and NAT2 subfamilies has been done largely on a historical basis of the research area and is a consensus nomenclature. 24 While this has been appropriate for most members of the genes for NAT, it has raised some confusion with the mouse, hamster and rat Nat2 genes, which encode for proteins with substrate specificity similar to human NAT1 (acetylate paminobenzoic acid; [25] [26] [27] [28] . At this stage, mouse is the only species to have three genes for NAT, pseudogenes excepted. Classification of different alleles into different clusters is based on the most significant nucleotide substitution present. 24 The prokaryotic genes are sufficiently dissimilar to the eukaryotic genes for NAT to preclude subclassification. Consequently, the prokaryotic genes are referred to as Nat only. An international committee has been established to oversee the nomenclature of the N-acetyltransferases. The committee is responsible for nomenclature updates and assignment of new alleles. This has been found to be essential to ensure consistence of allelic names in the literature. A Web site that provides information about the naming of existing and new alleles for all species can be found at http://www.louisville.edu/medschool/pharmacology/NAT. html.
REACTION MECHANISM AND SUBSTRATE SPECIFICITY
The arylamine N-acetyltransferases differ from the many other acetyl coenzyme A-dependent transferases present in cells because of their ping-pong bi bi reaction mechanism. 29, 30 The reaction takes place in two separate steps. Initially, acetyl coenzyme A binds to the enzyme and the acetyl moiety is transferred from the cofactor to a cysteine (Cys 68 for the human isoforms) of the protein. Coenzyme A is then released. The second step involves the binding of substrate to the acetylated enzyme following which the acetyl moiety is transferred to the substrate. Finally, the acetylated product is released from the enzyme. The first step of the reaction can proceed in the absence of arylamine substrate. 31 It may be that the enzyme exists in an acetylated state in the cell when no substrate is present, although this has not been shown to date, and the stability of the acetylated intermediate should be assessed.
There is no clear structural motif that determines substrate specificity for the different isoforms of NAT. In general, paminobenzoic acid (PABA), p-aminobenzoyl glutamate and p-aminosalicylic acid (PAS) are considered specific substrates for human NAT1 (or mouse NAT2). These substrates can be characterised by the presence of relatively small hydrophilic substitutions in the para position of the aromatic ring. By contrast, sulfamethazine, procainamide and dapsone are acetylated primarily by human NAT2. Some compounds such as 2-aminofluorene are excellent substrates for both human NAT1 and NAT2. 3 The prokaryotic NATs acetylate PABA poorly or not at all and their range of substrates, which includes isoniazid, suggests that they are functionally similar to the human NAT2 isoform. 32 However, the prokaryotic NATs are also capable of acetylating the human NAT1 specific substrate 5-aminosalicylic acid, 33 indicating that prokaryotic NATs should not be considered functionally equivalent to either NAT1 or NAT2 in humans. In some bacterial strains such as H. pylori, www.nature.com/tpj NAT activity has been reported although there is no evidence of a NAT-like gene in their genome. The very high K m values reported for substrates like PABA and 2-aminofluorene indicate that the acetylation reaction is very inefficient and is probably catalysed by a protein unrelated to the NATs. 34 One prokaryotic NAT homolog deserves further attention. The Rif gene cluster in A. mediterranei that encodes the proteins necessary for the synthesis of rifamycin B includes the gene RifF for rifamycin amide synthase. The amino acid similarity of RifF to the other prokaryotic NATs is approximately 45% (Figure 1 ) and the enzyme possesses the conserved catalytic triad in its amine terminus. RifF catalyses an amide bond formation during the latter stages of rifamycin synthesis ( Figure 3) . 22 Other NAT-like proteins may become evident as more genomes are sequenced and it is possible that the NAT protein has evolved in different species to undertake quite different cellular tasks.
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GENE LOCALISATION, STRUCTURE AND EXPRESSION
Two NAT isoenzymes have been identified in humans, namely NAT1 and NAT2, which are the products of distinct genetic loci, designated NAT1 and NAT2, respectively. 6 A related pseudogene, NATP1, has also been identified, 6 which contains multiple frameshift and nonsense mutations. The two functional NAT genes share an 87% nucleotide identity, which translates to an 81% homology at the amino acid level. While the entire transcript of NAT1 is derived from a single exon, that of NAT2 is derived from the protein encoding exon together with a second noncoding exon of 100 bp located about 8 kb upstream of the translation start site. 6, 35 Human NAT1 and NAT2, as well as NATP1, have been localised to the short arm of chromosome 8, 6 ,36 more specifically in region 8p22. 8 The NAT loci are separated by only 170-360 kb and are in the orientation NAT1 → NATP1 → NAT2, with NAT1 being on the centromeric side of marker D8S261 and NAT2 coinciding with marker D8S21. 36 Both NAT1 and NAT2 genes display pronounced allelic variation, with 26 different human NAT1 and 29 different human NAT2 alleles identified to date. 24 A similar situation is present in the mouse where three functional genes, designated Nat1, Nat2 and Nat3, have been identified to encode for NAT isoenzymes. 37, 38 Mouse NAT2 shows similar substrate specificity with human NAT1, while mouse NAT1 is capable of metabolising the human NAT2-specific substrate isoniazid. 39 To date, no specific substrate has been identified for NAT3, although the encoding locus appears to be functional. 38, 40 The localisation and genomic organisation of the mouse Nat genes is similar to their human counterparts. The three genes are clustered together in a 130-kb genomic region on mouse chromosome 8, cytogenetic band B3.1-B3.3 41 and within a genetic distance of about 31 cM from the centromere. 42 This chromosomal region is syntenic with the region harbouring the genes for human NAT on chromosome 8p. Polymorphism has been detected only in the Nat2 gene of both A/J 37 and A/HeJ 43 inbred mice, in the form of a missense A → T mutation at position 296 of the open reading frame, causing the slow acetylator phenotype. It is of interest that mouse Nat2 also possesses a short non-coding exon, located about 6 kb upstream of the intronless open reading frame. 41 This raises the possibility that mouse Nat2 may be the genetic orthologue of the human NAT2 gene, although mouse NAT2 and human NAT1 proteins appear to be functionally equivalent.
Information about the localisation and genomic organisation of the Nat genes in other eukaryotic species has been limited. All genes have an intronless open reading frame and polymorphism in NAT activity has been described in strains of rabbits, 44 hamsters 45 and rats, 46 all of which possess two Nat genes. Upstream non-coding exons have also been described for the rabbit Nat genes. 47 Cats and other felids only have one gene for NAT, 48 while dogs lack NAT activity, due to absence of Nat genes in their genome.
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HUMAN NATs
Human NAT2 Alleles Since the human NAT2 locus was established as the site of the classical acetylation polymorphism, 50,51 the study of NAT2 allelic variation has been an area of intense investigation. To date, 29 different NAT2 alleles have been detected in human populations (Table 1 ; reviewed in 15, 24, 52 ). Each of the variant alleles is comprised of between one and four nucleotide substitutions, of which 13 have been identified, located in the protein encoding region of the gene. Nine of these lead to a change in the encoded amino acid (C 190 ). Initial studies in liver tissue suggested that the slow acetylator phenotype associated with the presence of certain nucleotide substitutions in the protein encoding region of the NAT2 gene was due to a marked decrease in NAT2 protein content, while NAT2 mRNA levels remained unchanged. 57 Several studies have since investigated the mechanism by which nucleotide substitutions in the NAT2 gene affect acetylation capacity by the use of recombinant expression systems. [58] [59] [60] [61] [62] Hein and coworkers 63 performed a comprehensive study that assessed the acetylation capacity of 16 different NAT2 alleles in a bacterial expression system. Of the seven specific NAT2 substitutions that they examined, the T 341 C, G 590 A, G 857 A, and G 191 A substitutions produced recombinant NAT2 allozymes with reduced acetylation capacities, while the C 481 T, C 282 T, and A 803 G substitutions produced recombinant NAT2 allozymes with acetylation capacities similar to the wild-type NAT2 4 protein. As a result, NAT2 alleles that contain any of the specific substitutions that produced recombinant NAT2 allozymes with reduced acetylation capacities are associated with a slow acetylator phenotype, and include the NAT2 5, NAT2 6, NAT2 7, NAT2 14, and NAT2 17 clusters (see Table 1 ).
The molecular mechanisms responsible for the production of the slow acetylator phenotypes are not well understood at present. Some base changes appeared to cause a slow acetylation phenotype by producing an unstable protein. NAT2 allozymes encoded by alleles with base substitutions at positions 191, 590, or 857 were found to be significantly more unstable in bacterial expression systems than the wild-type protein. 52, 61, 64 However, in these studies the amount of immunodetectable NAT2 protein was not different upon expression of the variant and wild-type alleles. This is in contrast to the earlier observations by Grant and coworkers 57 who showed that liver NAT2 content was markedly reduced in slow acetylators, suggesting that the arti- A), expressed proteins that had N-and O-acetylation capacities similar to the expressed protein of the commonly occurring slow NAT2*5B allele, and significantly less than that of the wild-type NAT2*4 allele. The expression of NAT2 5B and NAT2 5D was found to be significantly lower than that of the wild-type protein, suggesting that the base substitution at position 341, which is common to the NAT2*5 cluster, is sufficient for reduction in NAT2 protein expression. This was not found to be the case for NAT2 6D and NAT2 14G, which were expressed at levels comparable to wild-type. By contrast, NAT2 6D and NAT2 14G were found to be significantly less stable than wild-type.
The frequency of the slow acetylator phenotype varies considerably among ethnic groups, 65 and this is due to the differing frequencies of the polymorphisms that correspond to the slow acetylator alleles. In Caucasian and African populations, the frequency of the slow acetylation phenotype varies between 40 and 70%, while that of Asian populations, such as Japanese, Chinese, Korean, and Thai, range from 10 to 30% (reviewed in 66 ). Caucasian and African populations have high frequencies of NAT2*5 alleles (Ͼ28%) and low frequencies of NAT2*7 alleles (Ͻ5%), while Asian populations have low incidences of NAT2*5 alleles www.nature.com/tpj (Ͻ7%) and higher incidences of NAT2*7 alleles (Ͼ10%). Also, NAT2*14 alleles are almost absent from Caucasian and Asian populations (Ͻ1%), but are present in African populations at comparably higher frequencies (Ͼ8%).
Human NAT1 Alleles
Historically, NAT1 was thought to be genetically invariant or monomorphic in nature. However, wide inter-individual variability in NAT1 activity towards PABA or PAS 51,67-72 was suggestive of a genetic polymorphism, but NAT1 activities were generally unimodally distributed. It wasn't until 1993 when Vatsis and Weber 73 first reported the existence of several allelic variations at the NAT1 locus that interest in the NAT1 gene was aroused, marking the beginning of a systematic survey of NAT1 genotypes. To date, 26 different NAT1 alleles have been detected in human populations (Table 2 ; reviewed in 15, 24, 52 ), however, only a small number have been shown to alter phenotype in vivo. Hughes and coworkers 17 used PAS as a probe drug to phenotype a population for NAT1 activity. By measuring urinary metabolite ratios, they were able to detect individuals with marked impairments of NAT1 function. However, there was only a moderate correlation between phenotypes determined by in vivo and in vitro methods, and the authors themselves suggest that less than 50% of the phenotypic variation observed in vivo was related to variation in NAT1 function. It appears that the measurement of NAT1 activity of blood cells is the most reliable method of phenotyping for NAT1. While little is known about the relative expression of NAT1 in various human tissues, studies in the rabbit model suggest that NAT1 activity is comparable in most tissues, including blood cells. 17 Therefore, it is reasonable to assume that NAT1 activity of blood cells is a good surrogate of systemic activity in humans.
The first report of a correlation between NAT1 genotype and phenotype was by Bell and coworkers in 1995. 74 They showed that the NAT1*10 allele was associated with activity two-fold higher than that of the wild-type allele, NAT1*4, in bladder and colon tissue samples. 74 In the bladder, higher levels of DNA adducts were detected in NAT1*10 heterozygotes compared with NAT1*4 homozygotes. 75, 76 The NAT1*10 allele also has been associated with a marginally elevated activity in liver samples 4 and erythrocytes. 77 NAT1* 10 has no mutations in the protein encoding region of the gene, but contains two nucleotide substitutions (T 1088 A and C 1095 A) in its 3′-untranslated region. The T 1088 A base change alters the consensus polyadenylation signal (AATAAA → AAAAAA) leading to the suggestion that increased activity may be due to enhanced mRNA stability. 74, 78 However, several recent studies, [16] [17] [18] 79, 80 do not support the idea that the NAT1*10 allele is associated with elevated NAT1 activity. As a result, the functional significance of this allele remains unclear at present.
A population study 16 showed a distribution of NAT1 activity that was clearly bimodal in nature, with 8% of the individuals being slow acetylators. Moreover, the above study was one of the first to report a correlation between NAT1 genotype and phenotype involving the slow acetyl- 
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Unknown T 1088 A, C 1095 A, None ⌬ 1025 ator alleles NAT1*14 and NAT1*17. Individuals that were heterozygous for either polymorphism had approximately half the activity of individuals that lacked these base changes. Furthermore, Western blots for NAT1 showed that low activity was due to a parallel decrease in NAT1 protein content, indicating that slow acetylator status was a result of a decrease in the amount of a functionally normal enzyme rather that the presence of a protein with altered acetylation capacity. A later study also found a correlation between NAT1 phenotype and the low activity NAT1*14 allele, 79 with heterozygote carriers of the allele having about 50% of the activity of noncarriers. Bruhn and coworkers 79 The Pharmacogenomics Journal also found that individuals who possessed a NAT1*11 allele had slightly lower activities compared with individuals who were homozygous for NAT1*4, NAT1*10, or NAT1*3, all of which had similar activities. Interestingly, the same study identified an individual who was homozygous for the NAT1*15 allele and who had no measurable NAT1 activity. The NAT1*15 allele contains a base substitution (C 559 T) in the protein encoding region of the NAT1 gene that introduces a stop codon, leading to the production of a truncated, inactive protein. 17 Hughes and coworkers 17 also identified an individual who possessed two low activity alleles, namely NAT1*14B/NAT1*15, and who subsequently had very low acetylation capacity. As with several NAT2 low activity alleles, there appears to be a gene-dosage effect for the low activity NAT1 alleles, with heterozygotes having about half the activity of NAT1*4 wild-type individuals, and homozygotes (or compound heterozygotes) for low activity alleles having little or no NAT1 activity. The exception is a NAT1*14A/NAT1*14B heterozygote identified by Payton and Sim, 77 whose activity was less than the NAT1*4 homozygotes but was still detectable. The frequency of slow acetylator alleles for NAT1 is low. The most common low activity allele, NAT1*14, has been identified in Caucasian populations ranging from 1.3 to 3.7%. [16] [17] [18] 79, 81, 82 Interestingly, a much higher frequency of the NAT1*14 allele (25%) was reported for a Lebanese population. 83 Since no homozygous individuals were identified in the above study, 50% of the Lebanese population had a slow acetylator genotype. This indicates that NAT1, like NAT2, shows considerable interethnic variability.
Some of the more common variant NAT1 alleles have been characterised in bacterial and/or mammalian expression systems. Recombinant expression of NAT1*14 in a bacterial system by Hughes and coworkers 17 showed that the variant protein had a 15-to 20-fold decrease in affinity for the substrate PAS and showed a 4-fold decrease in V max compared with recombinant NAT1 4 wild-type protein. The same study also showed that expression of NAT1*15 in E.coli produced a truncated protein that was totally inactive. Therefore, NAT1*14 (A and B) and NAT1*15 are low activity alleles, which is consistent with phenotyping studies using human blood cells. 16, 79, 81 Two other low activity alleles, NAT1*17 and NAT1*22, have been expressed in bacterial systems and both produced variant proteins that had no detectable NAT1 activity towards PAS. 18 Also, in the same study, immunoreactive NAT1 17 and NAT1 22 protein levels were markedly decreased compared with wild-type NAT1 4 protein levels. NAT1*19 was classified as a nonfunctional allele because the base substitution (C 97 T) introduces a premature stop codon. 18 The effects of coding and 3′-noncoding polymorphisms in the NAT1*11 allele were characterised by de Leon and coworkers 80 recently. Using recombinant expression of NAT1*11 in both bacterial and mammalian systems, they showed that no major differences existed in catalytic or other properties of the NAT1 11 protein compared with wild-type NAT1 4 protein. This is in agreement with an earlier study, 17 which showed that the activity of recombinant NAT1 4 and NAT1 11 were similar, but is in contrast to another study which reported a slightly reduced activity of blood cells from individuals who carried the NAT1*11 allele. 79 de Leon and coworkers, 80 using a mammalian expression system, have recently shown that the NAT1*16 phenotype is caused by polymorphism in the 3′-untranslated region that leads to a decrease in protein expression. NAT1*16 has a triple adenosine insertion on the 3′ side of the polyadenylation signal (AATAAA) which significantly alters the secondary structure of the pre-mRNA, leading to a 2-fold reduction in the amount of NAT1 16 protein and activity, compared with NAT1 4 and NAT1 10.
Some NAT1 alleles also may produce proteins with activities that are higher than that of the wild-type protein NAT1 4. Recombinant expression of NAT1*21, NAT1*24, and NAT1*25 in bacterial systems produced allozymes with activities 2-to 3-fold higher than NAT1 4. 18 However, the levels of immunoreactive protein expressed by NAT1*4, NAT1*21, NAT1*24, and NAT1*25 were equivalent. 18 The functional significance of the other NAT1 variants remains unclear at present.
NAT AND DISEASE
The association between acetylator status and the risk of various diseases has been extensively reported, and reviewed in detail. [84] [85] [86] [87] Altered risk with either the slow or rapid phenotype has been observed for bladder, colon and breast cancer, systemic lupus erythematosis, diabetes, Gilbert's disease, Parkinson's disease and Alzheimer's disease. These associations imply a role for environmental factors that are metabolised by the NATs, in particular NAT2, in each disorder. However, identifying those factors has remained elusive. Humans are exposed to many toxic NAT substrates including the food-derived heterocyclics present in the diet as well as arylamines such as 4-aminobiphenyl and ␤-naphthylamine present in tobacco smoke. [88] [89] [90] [91] Moreover, occupational exposure to arylamine carcinogens such as benzidine has also been reported. 92, 93 Because of the role of acetylation in the metabolic activation and detoxification of arylamine and heterocyclic carcinogens, acetylator status and cancer risk has been widely investigated. Unlike the relatively rare but highly penetrant genes involved in familial cancers, those genes responsible for metabolic polymorphisms have low penetrance and cause only a moderate increase in cancer risk. Nevertheless, their widespread occurrence in the general population suggests they are a significant contributor to individual risk. In 1979, Lower et al 94 first demonstrated an association between the slow acetylator phenotype and bladder cancer. This work was followed by many independent studies. However, few diseases have consistently demonstrated a relationship between phenotype and risk. For example, several studies have implicated the rapid phenotype as an increased risk factor for colon cancer, [95] [96] [97] whereas others have been unable to confirm this finding. [98] [99] [100] Geographical differences, ethnicity, lack of study power, dietary differences and differences in other risk factors between study groups have been suggested as reasons for variable results from indewww.nature.com/tpj pendent laboratories. Recent reports suggesting that NAT activity may be altered by environmental factors and substrate-dependent down-regulation 101 may also explain why inconsistent associations have been seen.
When acetylator phenotype has been linked to carcinogen exposure, more consistent results have been reported. For example, the rapid phenotype has emerged as a strong risk factor for colorectal cancer in those individuals who have a higher exposure to the food-derived heterocyclic amines. 99, 100, 102 These observations provide strong circumstantial evidence that the heterocyclic amines have an important role in colorectal cancer, and extensive animal studies support this. [103] [104] [105] [106] They also illustrate the importance of establishing associations between genetic polymorphisms and disease risk. From such studies, it should be possible to pursue the causative agent(s) of the disease where no obvious candidate agent is evident.
Recently, the NAT2 acetylator phenotype has been linked to increased risk associated with neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. [107] [108] [109] For late-onset Alzheimer's disease, an odds ratio of 3.0 (95% CI 1.3-7.3) has been reported for the rapid phenotype in non-apoE epsilon carriers. 109 By contrast, the slow phenotype appears to increase risk of Parkinson's disease with an odds ratio of 3.58 (95% CI 1.96-6.56). 107 Although these results need to be confirmed with larger epidemiological studies, they point to environmental factors that are substrates for the NATs having a role in the onset of these diseases. Alternatively, the different alleles for NAT2 that produce the rapid or slow phenotype may co-segregate with unrelated genes that are the causative agent for the different neurodegenerative diseases.
NAT and Drug Response
The genetic polymorphism in N-acetyltransferase activity was first discovered in patients treated with isoniazid for tuberculosis. 110 This drug is primarily excreted following acetylation catalysed by NAT2. Since then, many therapeutic agents have been shown to be polymorphically acetylated in humans. These include hydralazine, procainamide, sulphamethazine, endralazine, a number of sulphonamides, nitrazepam and dapsone. However, the incidence of failed or less effective clinical response as a consequence of acetylation polyphorphism is uncommon. This is because most drugs that are metabolised by the NATs have a wide therapeutic window or because acetylation is a minor metabolic pathway. An exception is hydralazine. Early studies showed that the antihypertensive activity of hydralazine was less in rapid acetylators and that a 40% higher dose was necessary for a similar therapeutic effect compared with slow acetylators. 111 This difference appeared to be due to a change in the bioavailability of the drug which decreased from 33% in slow acetylators to less than 10% in rapid acetylators. 112 A more common consequence of the polymorphic acetylation of therapeutic agents is an increase in the frequency and severity of side-effects associated with either the rapid or slow phenotype (Table 3) . These adverse effects often arise as the result of a shift in the metabolic pathways responsible for the activation and detoxification of the drug. This is best illustrated by the amine-containing sulphonamides, such as sulphamethoxazole, that undergo hydroxylation to a reactive N-hydroxy metabolite capable of covalently binding to macromolecules and giving rise to idiosyncratic adverse reactions. 113 These drugs can also be acetylated by NAT2 to non-reactive N-acetyl metabolites. In slow acetylators, a higher proportion of the drug is Nhydroxylated and consequently, these individuals are at a greater risk of sulphonamide-induced toxicity. [114] [115] [116] However, as pointed out by Spielberg, the incidence of severe adverse side effects to sulphonamides is much less than the incidence of the slow acetylator phenotype suggesting that other factors predispose individuals to idiosyncratic adverse reactions. 113 Risk of developing side effects, such as neurotoxicity or haemolytic anemia, to dapsone therapy is very similar to that described for the sulphonamides. 117 The most severe incidence of toxicity occurred in individuals with a slow acetylator phenotype who are rapid hydroxylators, which is consistent with the role each pathway has in the activation and detoxification of the drug. 118 While slow acetylators are at a greater risk of toxicity from sulphonamides and dapsone, other therapeutic agents exhibit increased incidence of adverse reactions in rapid acetylators. Amonafide is a novel arylamine that has previously been used in clinical trials for the treatment of various cancers. It undergoes N-acetylation to an active metabolite that contributes to systemic toxicity. Several studies have shown that myelosuppression is greater in rapid acetylators (white blood cell nadirs of 500 l −1 ) compared to slow acetylators (white blood cell nadirs of 3400 l −1 ) following a standard dose of 300 mg m −2 daily for 5 days. [119] [120] [121] . This has led to different recommended doses for the two groups.
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The recent discovery and cloning of prokaryotic NATs has raised the possibility that bacterial metabolism of drugs and other xenobiotics can contribute to their therapeutic and toxicological efficacy in vivo. 33, 123 Payton and associates showed that M. smegmatis transformed with the M. tuberculosis NAT gene has a 3-fold higher resistance to isoniazid due to an increase in acetylation of the drug. 123 These observations suggested that the level of NAT expression in target bacteria may be an important therapeutic modifier for antibiotics that are extensively acetylated. In addition, polymorphisms in the bacterial NAT genes could lead to different therapeutic responses.
Okumura et al 124 found that the acetylated metabolites of a range of arylamines such as p-aminobenzoic acid, 4-aminobiphenyl and 1-aminopyrene were excreted in the urine and feces of dogs that lack N-acetyltransferase activity. 49 They showed that the intestinal microflora were responsible for the formation of the acetyl derivatives. Similarly, the microflora in the intestine of rats contribute to the acetylation of 2-nitrofluorene and the formation of DNA adducts in liver, kidney, lung and heart following oral administration. 125 Taken together, these studies suggest that bacterial NAT has a role in the activation and detoxification of xenobiotics in the host organism and may play an important role in the metabolism of anti-inflammatory drugs, such as 5-aminosalicylic acid.
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CONCLUDING REMARKS
Although considerable allelic variation exists for both NAT1 and NAT2, our understanding of the molecular mechanisms and functional significance of many of these alleles, particularly for NAT1, is still limited. The majority of functional studies to date have been performed in bacterial expression systems, and the results of such studies may not necessarily accurately reflect what occurs in vivo, due to differences in degradation/processing pathways between bacterial and mammalian systems. Discrepancies between the two systems have been reported with regard to NAT protein content and slow acetylator alleles, and characterisation using mammalian systems may provide a better understanding of the molecular mechanisms leading to different NAT phenotypes.
Much of the research in the area of NATs has involved identifying relationships between allele frequencies and disease, particularly different forms of cancers. Although several studies have reported associations between different NAT alleles and various cancers, other studies have failed to do so. While these inconsistencies may be due to several factors, such as differences in exposure to arylamine carcinogens, it may well be that genotype does not necessarily accurately reflect phenotype. For example, although the regulation of NAT1 expression certainly has a genetic component, this only accounts for part of the observed variability in NAT1 activities. We have shown that significant variation in NAT1 activity can be observed within a single phenotype and within the same individuals measured on different occasions, suggesting that a considerable part of the variation in activity is environmentally based. In sup-port of this, we have recently provided evidence for substrate-dependent regulation of NAT1, 101 and identified a minimum promoter sequence for the human NAT1 that consists of an AP-1-like motif flanked on either side by a TCATT sequence (manuscript in preparation). Transient transfection assays showed that both the AP-1 motif and the 3′-TCATT sequence were essential for basal promoter activity, while the 5′-TCATT sequence appeared to act as an attenuator of phorbol 12-myristate 13-acetate induction. Moreover, antibody supershift assays suggested that c-jun, Oct-1, and YY1 transcription factors form complexes with the NAT1 minimum promoter. Therefore, environmental factors that alter the expression of transcription factors, such as those mentioned above also may modulate the basal expression of NAT1 in vivo. There also is the possibility that other promoter sequences and binding motifs exist further upstream from the minimum basal promoter sequence that could modulate NAT1 activity under certain conditions.
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